IRIS
VIAZZI, FRANCESCA CHIARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 17.623
Totale 17.623
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 17.623
Totale 17.623
Salva come PNG Salva come JPEG
Città #
Genova 12.477
Genoa 1.858
Rapallo 1.771
Vado Ligure 1.474
Bordighera 43
Totale 17.623
Salva come PNG Salva come JPEG
Nome #
Left ventricular dilatation and subclinical renal damage in primary hypertension 176
Early renal abnormalities as an indicator of cardiovascular risk in type 2 diabetes 165
Trend of eGFR in an Italian cohort of mother-to-child HIV-infected patients exposed to tenofovir for at least 2 years. 163
Increased renal resistive index in patients with essential hypertension: a marker of target organ damage. 151
Chronic kidney disease in hypertension under specialist care: the I-DEMAND study 150
Metabolic syndrome is associated with left ventricular dilatation in primary hypertension 145
Achievement of therapeutic targets in patients with diabetes and chronic kidney disease: Insights from the Associazione Medici Diabetologi Annals initiative 144
Association of kidney disease measures with risk of renal function worsening in patients with type 1 diabetes 144
Prevalent cardiac, renal and cardiorenal damage in patients with advanced abdominal aortic aneurysms 138
Ambulatory arterial stiffness index and renal abnormalities in primary hypertension 137
Novelty in hypertension in children and adolescents: Focus on hypertension during the first year of life, use and interpretation of ambulatory blood pressure monitoring, role of physical activity in prevention and treatment, simple carbohydrates and uric acid as risk factors 135
Impact of target organ damage assessment in the evaluation of global risk in patients with essential hypertension. 134
Antihypertensive Treatment and Renal Protection: the role of drugs inhibiting the renin-angiotensin-aldosterone system. 132
Peripheral artery disease and blood pressure profile abnormalities in hemodialysis patients 132
Insulin sensitivity of muscle protein metabolism is altered in patients with chronic kidney disease and metabolic acidosis. 131
Cardiovascular and renal effects of hyperuricaemia and gout. 130
The liver and the kidney: two critical organs influencing the atherothrombotic risk in metabolic syndrome. 130
C-reactive protein and target organ damage in untreated patients with primary hypertension. 130
Interorgan handling of fibroblast growth factor-23 in humans 130
Uric Acid Promotes Apoptosis in Human Proximal Tubule Cells by Oxidative Stress and the Activation of NADPH Oxidase NOX 4 130
Subclinical functional and structural renal abnormalities predict new onset type 2 diabetes in patients with primary hypertension 129
Vitamin D modulates the association of circulating insulin-like growth factor-1 with carotid artery intima-media thickness 128
Creatinine clearance and early signs of target organ damage in primary hypertension 124
Endothelin-1/nitric oxide balance and HOMA index in children with excess weight and hypertension: a pathophysiological model of hypertension 123
Combined effect of albuminuria and estimated glomerular filtration rate on cardiovascular events and all-cause mortality in uncomplicated hypertensive patients 122
Predicting cardiovascular risk using creatinine clearance and an artificial neural network in primary hypertension 122
Enhanced glomerular Toll-like receptor 4 expression and signaling in patients with type 2 diabetic nephropathy and microalbuminuria 121
Mild renal dysfunction and renal vascular resistance in primary hypertension 121
Variability in HbA1c, blood pressure, lipid parameters and serum uric acid, and risk of development of chronic kidney disease in type 2 diabetes 121
Combined use of urinary neutrophil gelatinase-associated lipocalin (uNGAL) and albumin as markers of early cardiac damage in primary hypertension. 121
Microalbuminuria identifies overall cardiovascular risk in essential hypertension: an artificial neural network-based approach. 120
METABOLIC SYNDROME AND CARDIOVASCULAR RISK IN PRIMARY HYPERTENSION. 120
Changes in renal resistive index and urinary albumin excretion in hypertensive patients under long-term treatment with lisinopril or nifedipine GITS 120
Natural history and risk factors for diabetic kidney disease in patients with T2D: lessons from the AMD-annals 120
Plasma Triglycerides and HDL-C Levels Predict the Development of Diabetic Kidney Disease in Subjects With Type 2 Diabetes: The AMD Annals Initiative 119
Metabolic syndrome is associated with early signs of organ damage in nondiabetic, hypertensive patients 119
Midwall fractional shortening identifies extracardiac organ damage in essential hypertension 118
Renin–angiotensin–aldosterone system blockade in chronic kidney disease: current strategies and a look ahead 118
Coronary flow reserve is impaired in hypertensive patients with subclinical renal damage 118
Apparent Treatment Resistant Hypertension, Blood Pressure Control and the Progression of Chronic Kidney Disease in Patients with Type 2 Diabetes 118
5,10-Methylenetetrahydrofolate reductase polymorphism and early organ damage in primary hypertension. 118
Mild hyperuricemia and subclinical renal damage in untreated primary hypertension 118
Inappropriate left ventricular mass is associated with microalbuminuria independently of left ventricular hypertrophy in primary hypertension 117
Antihyperglycemic treatment in patients with type 2 diabetes in Italy: The impact of age and kidney function 117
Overall health assessment: a renal perspective. 116
Toll-like receptor 4 signalling mediates inflammation in skeletal muscle of patients with chronic kidney disease 116
Metabolic syndrome and ambulatory arterial stiffness index in non-diabetic patients with primary hypertension. 116
Antihypertensive treatment and renal protection: Is there a J-curve relationship? 115
Uric acid and angiotensin II additively promote inflammation and oxidative stress in human proximal tubule cells by activation of toll-like receptor 4. 115
Renal and cardiac abnormalities in primary hypertension 114
Hyperuricemia and renal risk 114
Baseline hs-CRP predicts hypertension remission in metabolic syndrome 113
Causes and impact on survival of underuse of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in heart failure 113
Kidney disease measures are associated with the burden of coronary atherosclerosis, independently of diabetes 113
Global Cardiovascular Risk Assessment in the Management of Primary Hypertension: The Role of the Kidney 112
Blood pressure variability and multiple organ damage in primary hypertension 112
Microalbuminuria in primary hypertension: a guide to optimal patient management? 111
RAAS Inhibition and Renal Protection 110
Microalbuminuria and subclinical cerebrovascular damage in essential hypertension 109
Genetic polymorphism of the renin-angiotensin system and organ damage in essential hypertension 109
Can we predict outcome by noninvasive assessment of renal haemodynamics in hypertension? The role of renal resistive index 109
Association of kidney disease measures with risk of renal function worsening in patients with hypertension and type 2 diabetes 109
Chronic kidney disease and albuminuria in arterial hypertension. 109
Mild renal dysfunction and cardiovascular risk in hypertensive patients. 108
Antihypertensive Treatment in Diabetic Kidney Disease: The Need for a Patient-Centered Approach 107
SERUM URIC ACID AS A RISK FACTOR FOR CARDIOVASCULAR AND RENAL DISEASE AN OLD CONTROVERSY REVIVED. 106
Vascular permeability, blood pressure, and organ damage in primary hypertension 106
Serum uric acid as a marker of target organ damage in primary hypertension 105
Epidemiology of diabetic kidney disease in adult patients with type 1 diabetes in Italy: The AMD-Annals initiative 105
Kidney dysfunction and related cardiovascular risk factors among patients with type 2 diabetes 105
The Organ Handling of Soluble Klotho in Humans 105
Normoalbuminuric kidney impairment in patients with T1DM: Insights from annals initiative 103
Exploration into Uric and Cardiovascular Disease: Uric Acid Right for heArt Health (URRAH) Project, A Study Protocol for a Retrospective Observational Study 103
Five-Year Predictors of Insulin Initiation in People with Type 2 Diabetes under Real-Life Conditions 103
Sub-clinical organ damage in hypertension and obesity 102
Predictors of chronic kidney disease in type 2 diabetes: A longitudinal study from the AMD Annals initiative 102
Role of microalbuminuria in the assessment of cardiovascular risk in essential hypertension 102
Serum Uric Acid and Blood Pressure in Children at Cardiovascular Risk 102
Target organ damage and metabolic syndrome in non diabetic hypertensive patients 101
Global risk stratification in primary hypertension: the role of the kidney 101
Blood pressure, albuminuria and renal dysfunction: the 'chicken or egg' dilemma 101
Blood pressure status and the incidence of diabetic kidney disease in patients with hypertension and type 2 diabetes 101
Serum uric acid and risk of CKD in type 2 diabetes 100
Microalbuminuria and cardiovascular risk assessment in primary hypertension: should threshold levels be revised? 100
Cardiovascular and renal risk assessment as a guide for treatment in primary hypertension. 99
Increased urine semaphorin-3A is associated with renal damage in hypertensive patients with chronic kidney disease: a nested case-control study 99
Changes in albuminuria and cardiovascular risk under antihypertensive treatment: a systematic review and meta-regression analysis 99
MICROALBUMINURIA, CARDIOVASCULAR, AND RENAL RISK IN PRIMARY HYPERTENSION. 98
Serum uric acid levels predict new onset type 2 diabetes in hospitalized patients with primary hypertension: the MAGIC study. 98
Coronary flow reserve is impaired in uncomplicated hypertensive patients with renal dysfunction 98
Diabetic kidney disease in the elderly: Prevalence and clinical correlates 98
Metabolic syndrome and microalbuminuria predict renal outcome in non-diabetic patients with primary hypertension: the MAGIC study. 97
Microalbuminuria is a predictor of chronic renal insufficiency in patients without diabetes and with hypertension: the MAGIC Study 96
Evaluation of subclinical organ damage for risk assessment and treatment in the hypertensive patient: role of microalbuminuria. 96
Change in inferior vena cava minimum diameter during hospitalization predicts the readmission in patients with severe systolic heart failure 96
Prevalence and clinical correlates of microalbuminuria in essential hypertension: the MAGIC Study. Microalbuminuria: A Genoa Investigation on Complications. 95
Increased ambulatory arterial stiffness index is associated with target organ damage in primary hypertension 94
Left ventricular geometry and function in patients with essential hypertension and microalbuminuria 94
Metabolic syndrome, serum uric acid and renal risk in patients with T2D 94
Mild renal dysfunction and subclinical cardiovascular damage in primary hypertension. 93
Totale 11.566
Salva come PNG Salva come JPEG
Categoria #
all - tutte 61.415
article - articoli 59.863
book - libri 0
conference - conferenze 418
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.134
Totale 122.830
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204.114 0 0 0 0 455 621 794 368 502 738 483 153
2020/20211.949 85 228 167 172 99 129 173 203 138 239 127 189
2021/20222.261 98 98 107 231 90 236 130 528 130 253 81 279
2022/20232.179 206 143 20 230 329 382 31 173 385 29 211 40
2023/20241.503 69 162 43 192 125 277 94 103 64 35 110 229
2024/20251.584 143 327 194 321 599 0 0 0 0 0 0 0
Totale 18.196